{"id":55658,"date":"2023-04-11T02:03:22","date_gmt":"2023-04-11T00:03:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/"},"modified":"2023-04-11T02:03:22","modified_gmt":"2023-04-11T00:03:22","slug":"fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/","title":{"rendered":"FDA Authorizes Marketing of MISHA\u2122 Knee System for People Suffering from Knee Osteoarthritis"},"content":{"rendered":"
\n

\nImplantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement<\/i><\/p>\n

\nMISHA Knee System is implanted during an outpatient procedure; it’s the first and only device of its kind for people with symptomatic knee OA<\/i><\/p>\n

\nMore than 32 million people in the United States are affected by osteoarthritis<\/i><\/p>\n

FREMONT, Calif.–(BUSINESS WIRE)–Moximed<\/a>, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) granted marketing authorization of the MISHA\u2122 Knee System, an implantable shock absorber (ISA) for the knee. The MISHA Knee System is indicated to treat people with medial knee OA who failed to find relief from non-surgical or surgical treatment, continue to experience pain that interferes with daily activities, and are ineligible for, or unwilling to undergo, joint replacement due to age or absence of advanced OA.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cI’ve been lucky enough to have been exposed to many major orthopedic innovations, most notably total knee arthroplasty (TKA). TKA is a phenomenal operation, but it has its limitations. I still see a clinical void between arthroscopic knee preservation and arthroplasty,\u201d said Anil Ranawat, M.D., Chief, Hip and Knee Division of Sports Medicine Institute, Hospital for Special Surgery in New York. \u201cWith the FDA\u2019s clearance of the MISHA Knee System, millions of people with symptomatic knee OA will now have an opportunity to achieve high levels of pain relief, enjoy the lifestyle and activities that are important to them, and preserve the option for a primary knee arthroplasty in the future. This system fills that void for both surgeons and patients.\u201d<\/p>\n

\n\u201cKnee replacement is undoubtedly the gold standard for well-selected patients with severe OA, but for every patient I see that is ready for joint replacement, I see as many, if not more, who are not yet good arthroplasty candidates,\u201d said William A. Jiranek, M.D., former President of the American Association of Hip and Knee Surgeons (AAHKS). \u201cIn my current role as Vice Chair for Practice Innovation at Duke University, I consider treatments for OA across the entire disease continuum, rather than focusing only on the end stage. As such, I was invited to provide an independent, non-investigator assessment of Moximed\u2019s clinical study protocol, and I provided an independent, periodic review of the data during the study. I\u2019m excited that the study met its superiority composite endpoint, which included effectiveness and safety components. This new joint-preserving treatment provides arthritis surgeons the ability to intervene earlier in the disease process to help patients not ready for a joint replacement.\u201d<\/p>\n

\nMoximed utilized the clinically established benefits of load reduction on diseased joints to design the MISHA Knee System. Implanted during an outpatient-compatible procedure, the MISHA Knee System demonstrated superiority over high tibial osteotomy (HTO), a well-established surgery with decades of demonstrated clinical results, in its recent pivotal clinical study<\/a>.i<\/sup><\/p>\n

\n\u201cThis is a milestone event for knee OA sufferers, and it\u2019s the result of unwavering clinical research and development that spans more than 10 years. We offer special thanks to our study patients and surgeon investigators who helped advance the understanding of this new treatment for OA. Also, we recognize the dedicated reviewers at FDA for completing their thorough benefit-risk assessment of our breakthrough technology. We\u2019re thrilled to now be in a position to make the surgery available to patients,\u201d said Anton Clifford, PhD, founder and CEO of Moximed. \u201cWe are committed to providing excellent medical education and customer service, supporting selection and treatment of indicated patients, and demonstrating scalability of our business as we introduce the MISHA Knee System to the U.S.\u201d<\/p>\n

\nOsteoarthritis (OA) is a common, debilitating condition, affecting the lives of over 32 million adults in the U.S, and projected to impact 70 million Americans by 2040<\/a>. Knee OA develops when the joint\u2019s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation. Many people with mild to moderate OA are otherwise healthy, in their prime working years, and have busy lives to live. For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease. OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life.<\/p>\n

\nAbout Moximed<\/b><\/p>\n

\nMoximed was founded in 2008 and is dedicated to helping people with mild to moderate osteoarthritis preserve their knee joints while living healthy, active lives. The company\u2019s technology, the MISHA\u2122 Knee System, is the result of over a decade of clinical research and development and is the first implantable shock absorber being developed for the treatment of medial compartment knee osteoarthritis (OA). With experienced medtech leadership and strong investor support, Moximed is poised to elevate the standard of care and quality of life for millions of pre-arthroplasty knee OA sufferers hindered by arthritic knee pain and function loss. Moximed is based in Fremont, California.<\/p>\n

\nTo learn more, visit www.moximed.com<\/a>.<\/p>\n

\nAbout The MISHA\u2122 Knee System<\/b><\/p>\n

\nReducing weight on painful osteoarthritic joints is known to reduce pain and improve function. The MISHA\u2122 Knee System being developed is the first implantable shock absorber that reduces weight on the knee joint with every walking step, easing pain, preserving function, and possibly delaying joint replacement surgery. The implant is placed on the medial knee and moves with the natural joint, reducing about 30% of the peak force on the knee with every walking step.ii<\/sup><\/p>\n

\ni<\/sup> Diduch DR, Crawford DC, Ranawat AS, Victor J, Flanigan DC. Implantable Shock Absorber Provides Superior Pain Relief and Functional Improvement Compared With High Tibial Osteotomy in Patients with Mild-to-Moderate Medial Knee Osteoarthritis: A 2-Year Report. CARTILAGE. 2023;0(0). doi:10.1177\/19476035231157335.
\n
ii<\/sup> Morgan OJ, Hillstrom HJ, Ranawat A, Fragomen AT, Rozbruch SR, Hillstrom R. Effects of a Medial Knee Unloading Implant on Tibiofemoral Joint Mechanics During Walking. J Orthop Res. 2019;37(10):2149-2156. doi:10.1002\/jor.24379.<\/p>\n

Contacts<\/b> <\/p>\n

\nAnnika Parrish
\n
Health+Commerce
\n
annika@healthandcommerce.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement MISHA Knee System is implanted during an outpatient procedure; it’s the first and only device of its kind for people with symptomatic knee OA More than 32 million people in the United States are affected by … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55658","6":"format-standard","7":"category-industry"},"yoast_head":"\nFDA Authorizes Marketing of MISHA\u2122 Knee System for People Suffering from Knee Osteoarthritis - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Authorizes Marketing of MISHA\u2122 Knee System for People Suffering from Knee Osteoarthritis - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement MISHA Knee System is implanted during an outpatient procedure; it’s the first and only device of its kind for people with symptomatic knee OA More than 32 million people in the United States are affected by ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T00:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230410005434\/en\/1760272\/21\/MKT103259_MISHA_KNEE_SYSTEM_ANIMATION_WALKING.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"FDA Authorizes Marketing of MISHA\u2122 Knee System for People Suffering from Knee Osteoarthritis\",\"datePublished\":\"2023-04-11T00:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\\\/\"},\"wordCount\":1011,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005434\\\/en\\\/1760272\\\/21\\\/MKT103259_MISHA_KNEE_SYSTEM_ANIMATION_WALKING.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\\\/\",\"name\":\"FDA Authorizes Marketing of MISHA\u2122 Knee System for People Suffering from Knee Osteoarthritis - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005434\\\/en\\\/1760272\\\/21\\\/MKT103259_MISHA_KNEE_SYSTEM_ANIMATION_WALKING.jpg\",\"datePublished\":\"2023-04-11T00:03:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005434\\\/en\\\/1760272\\\/21\\\/MKT103259_MISHA_KNEE_SYSTEM_ANIMATION_WALKING.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005434\\\/en\\\/1760272\\\/21\\\/MKT103259_MISHA_KNEE_SYSTEM_ANIMATION_WALKING.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Authorizes Marketing of MISHA\u2122 Knee System for People Suffering from Knee Osteoarthritis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Authorizes Marketing of MISHA\u2122 Knee System for People Suffering from Knee Osteoarthritis - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/","og_locale":"en_US","og_type":"article","og_title":"FDA Authorizes Marketing of MISHA\u2122 Knee System for People Suffering from Knee Osteoarthritis - Pharma Trend","og_description":"Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement MISHA Knee System is implanted during an outpatient procedure; it’s the first and only device of its kind for people with symptomatic knee OA More than 32 million people in the United States are affected by ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-11T00:03:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230410005434\/en\/1760272\/21\/MKT103259_MISHA_KNEE_SYSTEM_ANIMATION_WALKING.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"FDA Authorizes Marketing of MISHA\u2122 Knee System for People Suffering from Knee Osteoarthritis","datePublished":"2023-04-11T00:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/"},"wordCount":1011,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230410005434\/en\/1760272\/21\/MKT103259_MISHA_KNEE_SYSTEM_ANIMATION_WALKING.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/","url":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/","name":"FDA Authorizes Marketing of MISHA\u2122 Knee System for People Suffering from Knee Osteoarthritis - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230410005434\/en\/1760272\/21\/MKT103259_MISHA_KNEE_SYSTEM_ANIMATION_WALKING.jpg","datePublished":"2023-04-11T00:03:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230410005434\/en\/1760272\/21\/MKT103259_MISHA_KNEE_SYSTEM_ANIMATION_WALKING.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230410005434\/en\/1760272\/21\/MKT103259_MISHA_KNEE_SYSTEM_ANIMATION_WALKING.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/fda-authorizes-marketing-of-misha-knee-system-for-people-suffering-from-knee-osteoarthritis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"FDA Authorizes Marketing of MISHA\u2122 Knee System for People Suffering from Knee Osteoarthritis"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55658"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55658\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}